sorafenib has been researched along with stx-0119 in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (stx-0119) | Trials (stx-0119) | Recent Studies (post-2010) (stx-0119) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 22 | 0 | 20 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Asai, A; Asakawa, N; Hirata, G; Kurita, A; Nishisaka, F; Ogo, N; Shishido, Y; Takagi, A; Takahashi, H; Taniguchi, K; Tsugane, M | 1 |
1 other study(ies) available for sorafenib and stx-0119
Article | Year |
---|---|
Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Interleukin-6; Mice; Molecular Docking Simulation; Mouth Neoplasms; Oxadiazoles; Protein Multimerization; Quinolines; Signal Transduction; Sorafenib; src Homology Domains; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays | 2020 |